Atlas/Track record
G12C: 15 trials since 2019. 14 reached Phase 1, 8 Phase 2, 0 Phase 3, 0 approved.
9 ongoing, 0 positive, 0 negative, 1 finished without posted results, 5 stopped early. Outcomes and badges come from the knowledge API as of 2026-11-02.
Where trials stop
Not in the data yet: why trials stopped. 5 of the 5 stopped trials have no classified reason yet (ClinicalTrials.gov “why stopped”, knowledge gap K1). They are counted as “reason not known yet”, never guessed.
Every trial, in order
| Start | Trial | Phase | Outcome | Status | Why stopped | |
|---|---|---|---|---|---|---|
| 2019-01 | NCT03785249↗ Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | Phase 1 / Phase 2 | Ongoing | Active not recruiting | — | |
| 2020-04 | NCT04330664↗ Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) | Phase 1 | Finished, no results posted | Completed | — | |
| 2021-07 | NCT04956640↗ Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Phase 1 / Phase 2 | Ongoing | Active not recruiting | — | |
| 2021-07 | NCT04975256↗ |